Literature DB >> 26722021

Using Epigenetic Therapy to Overcome Chemotherapy Resistance.

Julius Strauss1, William D Figg2.   

Abstract

It has been known for decades that as cancer progresses, tumors develop genetic alterations, making them highly prone to developing resistance to therapies. Classically, it has been thought that these acquired genetic changes are fixed. This has led to the paradigm of moving from one cancer therapy to the next while avoiding past therapies. However, emerging data on epigenetic changes during tumor progression and use of epigenetic therapies have shown that epigenetic modifications leading to chemotherapy resistance have the potential to be reversible with epigenetic therapy. In fact, promising clinical data exist that treatment with epigenetic agents can diminish chemotherapy resistance in a number of tumor types including chronic myelogenous leukemia, colorectal, ovarian, lung and breast cancer. The potential for epigenetic-modifying drugs to allow for treatment of resistant disease is exciting and clinical trials have just begun to evaluate this area. Copyright
© 2016 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.

Entities:  

Keywords:  Epigenetic therapy; chemotherapy resistance; review

Mesh:

Substances:

Year:  2016        PMID: 26722021      PMCID: PMC6388403     

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  29 in total

Review 1.  Oxidative stress as a mechanism of valproic acid-associated hepatotoxicity.

Authors:  Thomas K H Chang; Frank S Abbott
Journal:  Drug Metab Rev       Date:  2006       Impact factor: 4.518

2.  Retrospective review: re-treatment of patients with ovarian cancer with carboplatin after platinum resistance.

Authors:  H T See; R S Freedman; A P Kudelka; T W Burke; D M Gershenson; S Tangjitgamol; J J Kavanagh
Journal:  Int J Gynecol Cancer       Date:  2005 Mar-Apr       Impact factor: 3.437

3.  A role for methylation of the hMLH1 promoter in loss of hMLH1 expression and drug resistance in ovarian cancer.

Authors:  G Strathdee; M J MacKean; M Illand; R Brown
Journal:  Oncogene       Date:  1999-04-08       Impact factor: 9.867

4.  Reversal of drug resistance in human tumor xenografts by 2'-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter.

Authors:  J A Plumb; G Strathdee; J Sludden; S B Kaye; R Brown
Journal:  Cancer Res       Date:  2000-11-01       Impact factor: 12.701

5.  Approval summary: azacitidine for treatment of myelodysplastic syndrome subtypes.

Authors:  Edvardas Kaminskas; Ann Farrell; Sophia Abraham; Amy Baird; Li-Shan Hsieh; Shwu-Luan Lee; John K Leighton; Hasmukh Patel; Atiqur Rahman; Rajeshwara Sridhara; Yong-Cheng Wang; Richard Pazdur
Journal:  Clin Cancer Res       Date:  2005-05-15       Impact factor: 12.531

6.  Comparison of biological effects of non-nucleoside DNA methylation inhibitors versus 5-aza-2'-deoxycytidine.

Authors:  Jody C Chuang; Christine B Yoo; Jennifer M Kwan; Tony W H Li; Gangning Liang; Allen S Yang; Peter A Jones
Journal:  Mol Cancer Ther       Date:  2005-10       Impact factor: 6.261

7.  p21Waf1/Cip1 is a common target induced by short-chain fatty acid HDAC inhibitors (valproic acid, tributyrin and sodium butyrate) in neuroblastoma cells.

Authors:  Paola Rocchi; Roberto Tonelli; Consuelo Camerin; Stefania Purgato; Raffaele Fronza; Fabrizio Bianucci; Francesco Guerra; Andrea Pession; Anna Maria Ferreri
Journal:  Oncol Rep       Date:  2005-06       Impact factor: 3.906

8.  Reactivation of tumor suppressor genes by the cardiovascular drugs hydralazine and procainamide and their potential use in cancer therapy.

Authors:  Blanca Segura-Pacheco; Catalina Trejo-Becerril; Enrique Perez-Cardenas; Lucia Taja-Chayeb; Ignacio Mariscal; Alma Chavez; Carmen Acuña; Ana Maria Salazar; Marcela Lizano; Alfonso Dueñas-Gonzalez
Journal:  Clin Cancer Res       Date:  2003-05       Impact factor: 12.531

9.  Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study.

Authors:  Hagop Kantarjian; Jean-Pierre J Issa; Craig S Rosenfeld; John M Bennett; Maher Albitar; John DiPersio; Virginia Klimek; James Slack; Carlos de Castro; Farhad Ravandi; Richard Helmer; Lanlan Shen; Stephen D Nimer; Richard Leavitt; Azra Raza; Hussain Saba
Journal:  Cancer       Date:  2006-04-15       Impact factor: 6.860

10.  Bcr-Abl-independent imatinib-resistant K562 cells show aberrant protein acetylation and increased sensitivity to histone deacetylase inhibitors.

Authors:  Sang Min Lee; Jae Ho Bae; Mi Ju Kim; Hyun Sun Lee; Min Ki Lee; Byung Seon Chung; Dong Wan Kim; Chi Dug Kang; Sun Hee Kim
Journal:  J Pharmacol Exp Ther       Date:  2007-06-14       Impact factor: 4.030

View more
  12 in total

1.  Is the pharmaceutical industry's preoccupation with the monotherapy drug model stifling the development of effective new drug therapies?

Authors:  Ian Edwin Cock
Journal:  Inflammopharmacology       Date:  2018-05-07       Impact factor: 4.473

Review 2.  Epigenetic control of the tumor microenvironment.

Authors:  David L Marks; Rachel Lo Olson; Martin E Fernandez-Zapico
Journal:  Epigenomics       Date:  2016-10-04       Impact factor: 4.778

3.  A Glioblastoma Genomics Primer for Clinicians.

Authors:  John D Patterson; Thidathip Wongsurawat; Analiz Rodriguez
Journal:  Med Res Arch       Date:  2020-02-21

4.  Decitabine and vorinostat with FLAG chemotherapy in pediatric relapsed/refractory AML: Report from the therapeutic advances in childhood leukemia and lymphoma (TACL) consortium.

Authors:  Lauren Pommert; Eric S Schafer; Jemily Malvar; Nathan Gossai; Ellynore Florendo; Kirthi Pulakanti; Katelyn Heimbruch; Cary Stelloh; Yueh-Yun Chi; Richard Sposto; Sridhar Rao; Van Thu Huynh; Patrick Brown; Bill H Chang; Susan I Colace; Michelle L Hermiston; Kenneth Heym; Raymond J Hutchinson; Joel A Kaplan; Rajen Mody; Tracey A O'Brien; Andrew E Place; Peter H Shaw; David S Ziegler; Alan Wayne; Deepa Bhojwani; Michael J Burke
Journal:  Am J Hematol       Date:  2022-03-08       Impact factor: 13.265

Review 5.  Intratumoral Heterogeneity of the Epigenome.

Authors:  Tali Mazor; Aleksandr Pankov; Jun S Song; Joseph F Costello
Journal:  Cancer Cell       Date:  2016-04-11       Impact factor: 31.743

6.  Brain Tumor Biobank Development for Precision Medicine: Role of the Neurosurgeon.

Authors:  Emilie Darrigues; Benjamin W Elberson; Annick De Loose; Madison P Lee; Ebonye Green; Ashley M Benton; Ladye G Sink; Hayden Scott; Murat Gokden; John D Day; Analiz Rodriguez
Journal:  Front Oncol       Date:  2021-04-26       Impact factor: 6.244

Review 7.  DNA methylation: an epigenetic mark of cellular memory.

Authors:  Mirang Kim; Joseph Costello
Journal:  Exp Mol Med       Date:  2017-04-28       Impact factor: 8.718

Review 8.  Epigenetics in cancer therapy and nanomedicine.

Authors:  Annalisa Roberti; Adolfo F Valdes; Ramón Torrecillas; Mario F Fraga; Agustin F Fernandez
Journal:  Clin Epigenetics       Date:  2019-05-16       Impact factor: 6.551

9.  Improving drug discovery using image-based multiparametric analysis of the epigenetic landscape.

Authors:  Chen Farhy; Santosh Hariharan; Jarkko Ylanko; Luis Orozco; Fu-Yue Zeng; Ian Pass; Fernando Ugarte; E Camilla Forsberg; Chun-Teng Huang; David W Andrews; Alexey V Terskikh
Journal:  Elife       Date:  2019-10-22       Impact factor: 8.140

Review 10.  Past, Present and Future of Epigenetics in Adrenocortical Carcinoma.

Authors:  Madeleine Ettaieb; Thomas Kerkhofs; Manon van Engeland; Harm Haak
Journal:  Cancers (Basel)       Date:  2020-05-13       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.